This study encompassed seven cases of patients who underwent a transformation from EGFR-mutant non-small cell lung cancer (NSCLC) after receiving various TKIs (Gefitinib, Afatinib, Erlotinib, or Osimertinib), ultimately transitioning to small cell lung cancer (SCLC). Here, EGFR is linked to small cell lung carcinoma.